Presbia PLC (LENS) Upgraded at Jefferies Group
Several other research analysts also recently weighed in on LENS. TheStreet downgraded Presbia PLC from a hold rating to a sell rating in a research note on Thursday, September 1st. Zacks Investment Research upgraded Presbia PLC from a sell rating to a hold rating in a research note on Tuesday, July 26th. Finally, Rodman & Renshaw set a $14.00 price target on Presbia PLC and gave the stock a buy rating in a research note on Thursday, July 21st.
Presbia PLC (NASDAQ:LENS) traded down 2.4368% during midday trading on Tuesday, hitting $4.4001. The stock had a trading volume of 415 shares. The company has a 50-day moving average price of $4.40 and a 200-day moving average price of $4.53. The stock’s market cap is $58.68 million. Presbia PLC has a 52 week low of $2.94 and a 52 week high of $6.89.
About Presbia PLC
Presbia PLC is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The Company’s segment is the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States.
Receive News & Ratings for Presbia PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Presbia PLC and related companies with MarketBeat.com's FREE daily email newsletter.